Piper Jaffray analyst David Amsellem reiterated an Overweight rating and $14 price target on AcelRx Pharmaceuticals (NASDAQ: ACRX) saying following ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE